Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
640.12B
Market cap640.12B
Price-Earnings ratio
30.87
Price-Earnings ratio30.87
Dividend yield
1.98%
Dividend yield1.98%
Average volume
6.43M
Average volume6.43M
High today
$270.39
High today$270.39
Low today
$265.25
Low today$265.25
Open price
$268.44
Open price$268.44
Volume
4.70M
Volume4.70M
52 Week high
$281.07
52 Week high$281.07
52 Week low
$173.33
52 Week low$173.33

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $267.05, with a market capitalization of 640.12B. The stock trades at a price-to-earnings (P/E) ratio of 30.87 and offers a dividend yield of 1.98%.

During the trading session on 2026-09-11, Johnson & Johnson(JNJ) shares reached a daily high of $270.39 and a low of $265.25. At a current price of $267.05, the stock is +0.7% higher than the low and still -1.2% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 4.7M, versus its average volume of 6.43M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $173.33.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $173.33.

JNJ News

TipRanks 20m
Apollo Global in talks to buy J&J’s orthopedics unit, Bloomberg reports

Apollo Global Management (APO) is in talks to acquire the Johnson & Johnson (JNJ) orthopedics unit that the company has been looking to separate, Bloomberg’s Mi...

Bloomberg 34m
Apollo Global Is Said in Talks to Acquire J&J’s Orthopedics Unit - bloomberg.com

...

Apollo Global Is Said in Talks to Acquire J&J’s Orthopedics Unit - bloomberg.com
24/7 Wall St. 8h
These 5 Dividend Stocks Survived 2008, COVID and Every Recession Before Them

Investing These 5 Dividend Stocks Survived 2008, COVID and Every Recession Before Them Chasing the fattest yield on the screen is a trap most income investors f...

These 5 Dividend Stocks Survived 2008, COVID and Every Recession Before Them

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
25.9%
Sell
3.7%

More JNJ News

TipRanks 2d
Johnson & Johnson price target raised to $320 from $290 at HSBC

HSBC raised the firm’s price target on Johnson & Johnson to $320 from $290 and keeps a Buy rating on the shares. The firm adjusted targets in the healthcare gro...

Nasdaq 2d
Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage

Johnson & Johnson (NYSE:JNJ) MedTech Chairman Tim Schmid said the company remains confident it is delivering growth at the high end of its previously stated 5%...

Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage
Nasdaq 3d
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

Key Points iShares U.S. Pharmaceuticals ETF targets a specific subsector with 56 holdings, while iShares U.S. Healthcare ETF spans the broader industry with 10...

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?
24/7 Wall St. 3d
Want Dividends to Pay Your Medicare Premiums? Here's How Much You Need

Medicare Part B premiums keep climbing, and Social Security checks keep shrinking to cover them. Three Dividend Kings with very different yields and coverage pr...

Want Dividends to Pay Your Medicare Premiums? Here's How Much You Need
24/7 Wall St. 3d
JEPI Is an Income Machine—But These 3 Dividend Stocks Don't Cap Your Upside

ETF JEPI Is an Income Machine—But These 3 Dividend Stocks Don’t Cap Your Upside JEPI's monthly paycheck looks irresistible until you see exactly what the fund s...

JEPI Is an Income Machine—But These 3 Dividend Stocks Don't Cap Your Upside
24/7 Wall St. 4d
Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?

Investing Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble? Three defensive blue chips entered 2026 promising safe...

Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?
Simply Wall St 5d
Does IMAAVY’s Approval and Ongoing Talc Verdict Meaningfully Shift the Bull Case for Johnson & Johnson?

In August 2026, Johnson & Johnson received FDA approval for IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia in patients 12 and older, while...

Does IMAAVY’s Approval and Ongoing Talc Verdict Meaningfully Shift the Bull Case for Johnson & Johnson?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.